文献速递认知障碍与痴呆帕金森病与运动障碍

利斯的明在伴直立性低血压的帕金森病痴呆中的疗效

Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
PubMed 文献 · Ann Neurol · 2020-10-20

该研究对两项随机对照试验中1,047例帕金森病痴呆患者进行事后分析,评估直立性低血压(OH)是否影响利斯的明的认知获益。结果显示,OH+患者接受利斯的明治疗24周时ADAS-Cog改善优于OH-患者(安慰剂校正效应5.6±1.2 vs 1.9±0.9,p=0.0165),且利斯的明可能降低OH患病率。

要点

  • 伴OH的帕金森病痴呆患者使用利斯的明认知获益更大。
  • OH+患者中利斯的明胶囊76周MDRS改善优于贴剂。
  • 利斯的明可能具有直接降压作用,降低OH患病率。

核心结论

  • 伴直立性低血压的帕金森病痴呆患者从利斯的明获得的认知获益更大,可能由其直接抗低血压效应介导。

研究设计与样本

  • 对两项随机对照试验中1,047例帕金森病痴呆患者进行事后分析,比较24周利斯的明 vs 安慰剂(n=501)和76周利斯的明贴剂 vs 胶囊(n=546)。

主要发现

  • OH+组(n=288,27.5%)与OH-组(n=730,69.7%)总体安全性相当,但OH+安慰剂组晕厥发生率较高(9.2%)。
  • 24周时利斯的明对ADAS-Cog的安慰剂校正效应在OH+组为5.6±1.2,OH-组为1.9±0.9(p=0.0165)。
  • OH+患者中,76周时利斯的明胶囊较贴剂MDRS自基线变化更大(10.6±2.9 vs -1.5±3.0,p=0.031)。
  • 24周时利斯的明组OH总体患病率低于安慰剂组(28.3% vs 44.6%,p=0.0476)。

关键数值与推荐

  • 直立后收缩压下降≥20 mm Hg或舒张压下降≥10 mm Hg定义为OH阳性。
  • 主要终点为24周ADAS-Cog和76周MDRS,分别采用意向性治疗并检索脱落数据和观测病例分析。

临床怎么用

  • 对伴直立性低血压的帕金森病痴呆患者,利斯的明可能带来更明显的认知获益。
  • 伴OH患者选用利斯的明胶囊可能较贴剂在长期认知改善上更有优势。

局限性

  • 本研究为事后分析,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to evaluate if the cognitive benefit of rivastigmine is affected by the presence of orthostatic hypotension (OH) in patients with Parkinson's disease dementia (PDD). METHODS: We conducted a post hoc analysis on 1,047 patients with PDD from 2 randomized controlled trials comparing rivastigmine versus placebo at week 24 (n = 501) and rivastigmine patch versus capsule at week 76 (n = 546). A drop ≥ 20 mm Hg in systolic blood pressure (SBP) or ≥ 10 in diastolic blood pressure (DBP) upon standing classified subjects as OH positive (OH+); otherwise, OH negative (OH-). The primary end point was the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog) at week 24 and the Mattis Dementia Rating Scale (MDRS) at week 76, using intention-to-treat with retrieved dropout at week 24 and observed cases at week 76, consistent with the original analyses. RESULTS: Overall safety was comparable between OH+ (n = 288, 27.5%) and OH- (n = 730, 69.7%), except for higher frequency of syncope (9.2%) in the OH+ placebo arm. The placebo-adjusted effect of rivastigmine on ADAS-Cog at week 24 was 5.6 ± 1.2 for OH+ and 1.9 ± 0.9 in OH- (p = 0.0165). Among subjects with OH, the MDRS change from baseline at week 76 was higher for rivastigmine capsules versus patch (10.6 ± 2.9 vs -1.5 ± 3.0, p = 0.031). The overall prevalence of OH was lower for rivastigmine than placebo at week 24 (28.3% vs 44.6%, p = 0.0476). INTERPRETATION: The cognitive benefit from rivastigmine is larger in patients with PDD with OH, possibly mediated by a direct antihypotensive effect. ANN NEUROL 2021;89:91-98.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Espay AJ, Marsili L, Mahajan A, et al. Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Ann Neurol. 2020. PMID: 33016374. doi:10.1002/ana.25923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。